HKSE •
Healthcare •
Drug Manufacturers - Specialty & Generic •
Quote as of 09/11/2026 16:08
Company Profile
IndustryDrug Manufacturers - Specialty & Generic
SectorHealthcare
ExchangeHKSE
Market Capitalization19,015 mln
Float528 mln
Earnings Date03/04/2027
EPS
0.16
Overpriced
P / E
127
Highly speculative
Piotroski F-Score
4
/ 9
Borderline
Beneish M-Score
-1.24
Manipulation likely
1-Year Forecast
31.09
Exceptional upside
Relative Strength
78
/ 100
Strongly outperforming
Business Description
HUTCHMED (China) Limited is a Hong Kong-based biopharmaceutical company founded in 2000 that researches and brings to market treatments for cancer and immune system disorders across global markets. The company has built a broad portfolio of drug candidates targeting a wide range of conditions, including colorectal cancer, lung cancer, leukemia, and autoimmune blood disorders, with several products already approved and others advancing through clinical trials. HUTCHMED works alongside major pharmaceutical partners such as AstraZeneca, Lilly, and Takeda to accelerate the development and distribution of its medicines.
